Novavax reported $2.75B in Assets for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Adamas Pharmaceuticals ADMS:US 150.64M 18.6M
Adma Biologics ADMA:US $ 232.81M 2.85M
Agenus AGEN:US $ 192.3M 42.62M
Astrazeneca AZN:US $ 73641M 8715M
AstraZeneca AZN:LN 73641M 8715M
Biocryst Pharmaceuticals BCRX:US $ 277.28M 7.15M
BioSpecifics Technologies BSTC:US 137.27M 3.49M
Dynavax Technologies DVAX:US $ 647.91M 157.79M
Genocea Biosciences GNCA:US $ 77.38M 6.56M
GlaxoSmithKline GSK:LN 77011M 1068M
Kindred Biosciences KIN:US $ 108.87M 1.11M
Mannkind MNKD:US $ 252.79M 66.59M
Minerva Neurosciences NERV:US $ 105.32M 6.51M
Moderna Inc MRNA:US 16.15B 3.46B
Novartis NVS:US $ 124015M 2263M
Novavax NVAX:US $ 2749.59M 141.22M
Pain Therapeutics PTIE:US $ 281.3M 2.74M
Peregrine Pharmaceuticals PPHM:US $ 270.53M 5.02M
Sarepta Therapeutics SRPT:US $ 2759.07M 6.16M
Tg Therapeutics TGTX:US $ 481.4M 67.3M